Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly …
…, D Gargot, F Subtil, V Le Brun-Ly, J Cretin… - Journal of Clinical …, 2013 - hal.science
Purpose: Elderly patients form a heterogeneous population. Evaluation of geriatric factors
may help evaluate a patient's health status to better adapt treatment. Patients and Methods: …
may help evaluate a patient's health status to better adapt treatment. Patients and Methods: …
[HTML][HTML] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset …
…, C Brown, D Lorusso, T Dell'Anna, J Cretin… - European Journal of …, 2015 - Elsevier
Aim To perform a subset analysis of patients with very platinum-sensitive recurrent ovarian
cancer (ROC) enrolled in the phase III CALYPSO trial. Patients and methods The …
cancer (ROC) enrolled in the phase III CALYPSO trial. Patients and methods The …
HER 2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a F rench regional cohort
…, S Thibault, G Romieu, A Mathieu, J Cretin… - Cancer …, 2014 - Wiley Online Library
The management of pT1a‐bN0M0 breast cancer remains an area of controversy. Data from
714 patients classified as having pT1a‐bN0M0 breast cancer and treated, from 1999 to 2004 …
714 patients classified as having pT1a‐bN0M0 breast cancer and treated, from 1999 to 2004 …
[HTML][HTML] Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients
…, D Gargot, L Teillet, E Maillard, D Genet, J Cretin… - European Journal of …, 2017 - Elsevier
Aim Several predictors of metastatic colorectal cancer (mCRC) outcomes have been
described. Specific geriatric characteristics could be of interest to determine prognosis. Method …
described. Specific geriatric characteristics could be of interest to determine prognosis. Method …
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study
…, N Gane, D Pissaloux, N Bonnin, T Petit, J Cretin… - Targeted …, 2013 - Springer
This study aimed to determine whether the expression of various tumor biomarkers of the
mTOR pathway predicts tumor response to everolimus in metastatic recurrent endometrial …
mTOR pathway predicts tumor response to everolimus in metastatic recurrent endometrial …
Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of GETUG 14 randomized …
…, JM Hannoun-Levi, TD Nguyen, C Hennequin, J Cretin… - 2016 - ascopubs.org
5021 Background: Multi-center randomized trial to evaluate the addition of 4-month
androgen deprivation to high dose radiotherapy in intermediate risk localized prostate …
androgen deprivation to high dose radiotherapy in intermediate risk localized prostate …
[HTML][HTML] Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized …
…, F Hocine, J Martin, V Le Brun-Ly, J Cretin… - Digestive and Liver …, 2023 - Elsevier
Background Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant
chemotherapy improved disease-free survival after stage III colon cancer resection, but …
chemotherapy improved disease-free survival after stage III colon cancer resection, but …
Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial
…, H Orfeuvre, M Combe, C Platini, J Cretin… - Anticancer …, 2009 - ar.iiarjournals.org
Background: The GINECO group previously demonstrated that pegylated liposomal
doxorubicin (PLD)-carboplatin combination was an effective and well-tolerated treatment for …
doxorubicin (PLD)-carboplatin combination was an effective and well-tolerated treatment for …
[HTML][HTML] Telomere length is a prognostic biomarker in elderly advanced ovarian cancer patients: a multicenter GINECO study
…, B Horard, A Bruyas, E Legouffe, J Cretin… - Aging (Albany …, 2015 - ncbi.nlm.nih.gov
… Claire Falandry, 1 Béatrice Horard, 2 Amandine Bruyas, 3 Eric Legouffe, 4 Jacques Cretin,
5 Jérôme Meunier, 6 Jérôme Alexandre, 7 Valérie Delecroix, 8 Michel Fabbro, 9 Marie-Noëlle …
5 Jérôme Meunier, 6 Jérôme Alexandre, 7 Valérie Delecroix, 8 Michel Fabbro, 9 Marie-Noëlle …
Non-pegylated liposomal doxorubicin (NPLD, Myocet®)+ carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
…, E Kalbacher, O Cojocarasu, M Fabbro, J Cretin… - Gynecologic …, 2019 - Elsevier
Background Carboplatin and pegylated liposomal doxorubicin combination is a standard
regimen in platinum-sensitive recurrent ovarian cancer patients. The pegylated liposomal …
regimen in platinum-sensitive recurrent ovarian cancer patients. The pegylated liposomal …